{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:41:55Z","timestamp":1780605715403,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,28]]},"DOI":"10.7759\/cureus.86935","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T03:52:48Z","timestamp":1751169168000},"source":"Crossref","is-referenced-by-count":1,"title":["Early-Onset Ramsay Hunt Syndrome After Pembrolizumab Administration in a Patient With Lung Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Satoshi","family":"Furuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow MA","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015, 33:1974-82. 10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-33. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi S","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","volume":"77","author":"Morelli T","year":"2022","unstructured":"Morelli T, Fujita K, Redelman-Sidi G, Elkington PT. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2022, 77:304-11. 10.1136\/thoraxjnl-2021-217260","journal-title":"Thorax"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.2.149","article-title":"Ramsay Hunt syndrome","volume":"71","author":"Sweeney CJ","year":"2001","unstructured":"Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry. 2001, 71:149-54. 10.1136\/jnnp.71.2.149","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6444-0","article-title":"Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report","volume":"19","author":"Sakoh T","year":"2019","unstructured":"Sakoh T, Kanzaki M, Miyamoto A, et al.. Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. BMC Cancer. 2019, 19:1220. 10.1186\/s12885-019-6444-0","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0385-8146(99)00049-8","article-title":"A comparison and conversion table of 'the House-Brackmann facial nerve grading system' and 'the Yanagihara grading system'","volume":"27","author":"Satoh Y","year":"2000","unstructured":"Satoh Y, Kanzaki J, Yoshihara S. A comparison and conversion table of 'the House-Brackmann facial nerve grading system' and 'the Yanagihara grading system'. Auris Nasus Larynx. 2000, 27:207-12. 10.1016\/s0385-8146(99)00049-8","journal-title":"Auris Nasus Larynx"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14074","article-title":"Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients","volume":"45","author":"Sueki H","year":"2018","unstructured":"Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. J Dermatol. 2018, 45:3-9. 10.1111\/1346-8138.14074","journal-title":"J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2764","article-title":"Herpes zoster in lung cancer patients treated with PD-1\/PD-L1 inhibitors","volume":"11","author":"Taoka M","year":"2022","unstructured":"Taoka M, Ochi N, Yamane H, et al.. Herpes zoster in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Transl Cancer Res. 2022, 11:456-62. 10.21037\/tcr-21-2764","journal-title":"Transl Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0318","article-title":"Herpes zoster in patients with lung cancer treated with PD-1\/PD-L1 antibodies","volume":"14","author":"Nagai Y","year":"2022","unstructured":"Nagai Y, Sata M, Ohta H, et al.. Herpes zoster in patients with lung cancer treated with PD-1\/PD-L1 antibodies. Immunotherapy. 2022, 14:1211-7. 10.2217\/imt-2021-0318","journal-title":"Immunotherapy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo M","year":"2016","unstructured":"Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016, 63:1490-3. 10.1093\/cid\/ciw539","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900890","article-title":"Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype","volume":"183","author":"van Velzen M","year":"2009","unstructured":"van Velzen M, Laman JD, Kleinjan A, Poot A, Osterhaus AD, Verjans GM. Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype. J Immunol. 2009, 183:2456-61. 10.4049\/jimmunol.0900890","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/v14112517","article-title":"Activation of interferon-stimulated genes following varicella-zoster virus infection in a human iPSC-derived neuronal in vitro model depends on exogenous interferon-\u03b1","volume":"14","author":"Boeren M","year":"2022","unstructured":"Boeren M, Van Breedam E, Buyle-Huybrecht T, et al.. Activation of interferon-stimulated genes following varicella-zoster virus infection in a human iPSC-derived neuronal in vitro model depends on exogenous interferon-\u03b1. Viruses. 2022, 14:10.3390\/v14112517","journal-title":"Viruses"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy403","article-title":"Immunobiology of varicella-zoster virus infection","volume":"218","author":"Laing KJ","year":"2018","unstructured":"Laing KJ, Ouwendijk WJ, Koelle DM, Verjans GM. Immunobiology of varicella-zoster virus infection. J Infect Dis. 2018, 218:S68-74. 10.1093\/infdis\/jiy403","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040778","article-title":"Human herpesvirus and the immune checkpoint PD-1\/PD-L1 pathway: disorders and strategies for survival","volume":"9","author":"Murata T","year":"2021","unstructured":"Murata T. Human herpesvirus and the immune checkpoint PD-1\/PD-L1 pathway: disorders and strategies for survival. Microorganisms. 2021, 9:10.3390\/microorganisms9040778","journal-title":"Microorganisms"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100548","article-title":"Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)","volume":"7","author":"Pedrazzoli P","year":"2022","unstructured":"Pedrazzoli P, Lasagna A, Cassaniti I, et al.. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open. 2022, 7:100548. 10.1016\/j.esmoop.2022.100548","journal-title":"ESMO Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341970-early-onset-ramsay-hunt-syndrome-after-pembrolizumab-administration-in-a-patient-with-lung-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T03:52:49Z","timestamp":1751169169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341970-early-onset-ramsay-hunt-syndrome-after-pembrolizumab-administration-in-a-patient-with-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.86935","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,28]]}}}